Key facts
- Eyego’s last known valuation is $6.1M (Jun 2023).
- It has raised $7.1M; the latest was Later Stage VC in May 2025.
- Notable investors include Maj Invest, Accelerace, Bo Kruse, Borean Innovation, Innovationsfonden — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Eyego
- ·The full record, as it builds
Funding rounds
No funding rounds for Eyego are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Eyego
Developer of topical eye medication designed to treat glaucoma. The company develops eye care technologies that improve the quality of life of people around the world suffering from severe and chronic eye conditions, such as dry eye disease (DED) and glaucoma, and offers topical eye medication that uses a misting technology to provide redefined eye drops, providing patients suffering from severe and chronic eye conditions with new-age treatments.
- Sector
- Healthcare
- HQ
- Hoersholm, Denmark
- Founded
- 2015
- Employees
- 7
- Website
- eye-go.com/
- Ownership
- Privately Held (backing)
Eyego doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eyego shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eyego in its N-PORT filings yet. We sweep new filings monthly.